Covid-19 Research

Opinion

Omitting Axillary Dissection in Breast Cancer with Sentinel Node Metastases. Extending Axillary Surgical De Escalation

Journal of Biomedical Research & Environmental Sciences article abstract with citation details, DOI, publication dates, subject areas, full text links, and references.

View DOI Submit Manuscript

Article Details

Publication record, authors, dates, abstract, and full text access.

Open Access
Article Type Opinion
Subject Medicine Group
OCLC JBRES Record
Gilles Houvenaeghel*, Monique Cohen and Alexandre de Nonneville
Issue: Volume5-Issue12
Pages: 1597-1601
Received: 2024-12-11
Accepted: 2024-12-24
Published: 2024-12-26

Abstract

FullText HTML FullText PDF DOI: 10.37871/jbres2046 Crossmark

Certificate of Publication

Certificate of Publication

Copyright

© 2024 Houvenaeghel G, et al. Distributed under Creative Commons CC-BY 4.0 Creative CommonsAttribution

How to cite this article

Houvenaeghel G, Cohen M, de Nonneville A. Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases. Extending Axillary Surgical De-Escalation. J Biomed Res Environ Sci. 2024 Dec 26; 5(12): 1597-1601. doi: 10.37871/jbres2046, Article ID: JBRES2046, Available at: https://www.jelsciences.com/articles/jbres2046.pdf

Subject area(s)

OncologySurgery

References

  1. Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Ashikaga T, Weaver DL, Miller BJ, Jalovec LM, Frazier TG, Noyes RD, Robidoux A, Scarth HM, Mammolito DM, McCready DR, Mamounas EP, Costantino JP, Wolmark N; National Surgical Adjuvant Breast and Bowel Project. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007 Oct;8(10):881-8. doi: 10.1016/S1470-2045(07)70278-4. PMID: 17851130.
  2. Houvenaeghel G, Quilichini O, Cohen M, Reyal F, Classe JM, Mazouni C, Giard S, Carrabin N, Charitansky H, Darai E, Hudry D, Azuar P, Villet R, Gimbergues P, Tunon-DE-Lara C, Lambaudie E. Sentinel lymph node biopsy validation for large tumors. Int J Surg. 2017 Dec;48:275-280. doi: 10.1016/j.ijsu.2017.10.077. Epub 2017 Nov 24. PMID: 29175020.
  3. de Boniface J, Filtenborg Tvedskov T, Rydén L, Szulkin R, Reimer T, Kühn T, Kontos M, Gentilini OD, Olofsson Bagge R, Sund M, Lundstedt D, Appelgren M, Ahlgren J, Norenstedt S, Celebioglu F, Sackey H, Scheel Andersen I, Hoyer U, Nyman PF, Vikhe Patil E, Wieslander E, Dahl Nissen H, Alkner S, Andersson Y, Offersen BV, Bergkvist L, Frisell J, Christiansen P; SENOMAC Trialists’ Group; SENOMAC Trialists' Group. Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases. N Engl J Med. 2024 Apr 4;390(13):1163-1175. doi: 10.1056/NEJMoa2313487. PMID: 38598571.
  4. Tinterri C, Canavese G, Gatzemeier W, Barbieri E, Bottini A, Sagona A, Caraceni G, Testori A, Di Maria Grimaldi S, Dani C, Boni L, Bruzzi P, Fernandes B, Scorsetti M, Zambelli A, Gentile D; SINODAR-ONE Collaborative Group. Sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer patients undergoing mastectomy with one to two metastatic sentinel lymph nodes: sub-analysis of the SINODAR-ONE multicentre randomized clinical trial and reopening of enrolment. Br J Surg. 2023 Aug 11;110(9):1143-1152. doi: 10.1093/bjs/znad215. PMID: 37471574; PMCID: PMC10492188.
  5. Houvenaeghel G, Cohen M, Raro P, De Troyer J, Gimbergues P, Tunon de Lara C, Ceccato V, Vaini-Cowen V, Faure-Virelizier C, Marchal F, Gauthier T, Jouve E, Theret P, Regis C, Gabelle P, Pernaut J, Del Piano F, D'Halluin G, Lantheaume S, Darai E, Beedassy B, Dhainaut-Speyer C, Martin X, Girard S, Villet R, Monrigal E, Hoyek T, Le Brun JF, Colombo PE, Tallet A, Boher JM; SERC trial group. Sentinel node involvement with or without completion axillary lymph node dissection: treatment and pathologic results of randomized SERC trial. NPJ Breast Cancer. 2021 Oct 8;7(1):133. doi: 10.1038/s41523-021-00336-3. PMID: 34625562; PMCID: PMC8501060.
  6. Houvenaeghel G, Cohen M, Sabiani L, Martino M, Heinemann M, Chauvet MP. Sentinel lymph node biopsy validation for pt3 breast cancer. Int J Surg.
  7. Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, Ollila DW, Hansen NM, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, Hunt KK, Morrow M. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA. 2017 Sep 12;318(10):918-926. doi: 10.1001/jama.2017.11470. PMID: 28898379; PMCID: PMC5672806.
  8. de Boniface J, Appelgren M, Szulkin R, Alkner S, Andersson Y, Bergkvist L, Frisell J, Gentilini OD, Kontos M, Kühn T, Lundstedt D, Offersen BV, Olofsson Bagge R, Reimer T, Sund M, Christiansen P, Rydén L, Filtenborg Tvedskov T; SENOMAC Trialists’ Group. Completion axillary lymph node dissection for the identification of pN2-3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial. Lancet Oncol. 2024 Sep;25(9):1222-1230. doi: 10.1016/S1470-2045(24)00350-4. Epub 2024 Aug 6. PMID: 39121881.
  9. Rastogi P, O'Shaughnessy J, Martin M, Boyle F, Cortes J, Rugo HS, Goetz MP, Hamilton EP, Huang CS, Senkus E, Tryakin A, Cicin I, Testa L, Neven P, Huober J, Shao Z, Wei R, André V, Munoz M, San Antonio B, Shahir A, Harbeck N, Johnston S. Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes. J Clin Oncol. 2024 Mar 20;42(9):987-993. doi: 10.1200/JCO.23.01994. Epub 2024 Jan 9. Erratum in: J Clin Oncol. 2024 Jun 10;42(17):2111. doi: 10.1200/JCO.24.00711. Erratum in: J Clin Oncol. 2025 Jan;43(1):113. doi: 10.1200/JCO-24-02469. PMID: 38194616; PMCID: PMC10950161.
  10. Houvenaeghel G, Heinemann M, Classe JM, Bouteille C, Gimbergues P, Azuar AS, Martino M, Tallet A, Cohen M, de Nonneville A. Omission of Completion Axillary Lymph Node Dissection for Patients with Breast Cancer Treated by Upfront Mastectomy and Sentinel Node Isolated Tumor Cells or Micrometastases. Cancers (Basel). 2024 Jul 26;16(15):2666. doi: 10.3390/cancers16152666. PMID: 39123393; PMCID: PMC11312260.
  11. Bartels SAL, Donker M, Poncet C, Sauvé N, Straver ME, van de Velde CJH, Mansel RE, Blanken C, Orzalesi L, Klinkenbijl JHG, van der Mijle HCJ, Nieuwenhuijzen GAP, Veltkamp SC, van Dalen T, Marinelli A, Rijna H, Snoj M, Bundred NJ, Merkus JWS, Belkacemi Y, Petignat P, Schinagl DAX, Coens C, van Tienhoven G, van Duijnhoven F, Rutgers EJT. Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial. J Clin Oncol. 2023 Apr 20;41(12):2159-2165. doi: 10.1200/JCO.22.01565. Epub 2022 Nov 16. PMID: 36383926.
  12. Solá, M.; Alberro, J.A.; Fraile, M.; Santesteban, P.; Ramos, M.; Fabregas, R.; Moral, A.; Ballester, B.; Vidal, S. Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis: Final results from the multicenter clinical trial AATRM 048/13/2000. Ann. Surg. Oncol. 2013, 20, 120–127.
  13. Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, Baratella P, Chifu C, Sargenti M, Intra M, Gentilini O, Mastropasqua MG, Mazzarol G, Massarut S, Garbay JR, Zgajnar J, Galatius H, Recalcati A, Littlejohn D, Bamert M, Colleoni M, Price KN, Regan MM, Goldhirsch A, Coates AS, Gelber RD, Veronesi U; International Breast Cancer Study Group Trial 23-01 investigators. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol. 2013 Apr;14(4):297-305. doi: 10.1016/S1470-2045(13)70035-4. Epub 2013 Mar 11. Erratum in: Lancet Oncol. 2013 Jun;14(7):e254. PMID: 23491275; PMCID: PMC3935346.
  14. Houvenaeghel G, Cohen M, Raro P, De Troyer J, Gimbergues P, Tunon de Lara C, Ceccato V, Vaini-Cowen V, Faure-Virelizier C, Marchal F, Gauthier T, Jouve E, Theret P, Regis C, Gabelle P, Pernaut J, Del Piano F, D'Halluin G, Lantheaume S, Darai E, Beedassy B, Dhainaut-Speyer C, Martin X, Girard S, Villet R, Monrigal E, Hoyek T, Le Brun JF, Colombo PE, Tallet A, Boher JM; SERC trial group. Sentinel node involvement with or without completion axillary lymph node dissection: treatment and pathologic results of randomized SERC trial. NPJ Breast Cancer. 2021 Oct 8;7(1):133. doi: 10.1038/s41523-021-00336-3. PMID: 34625562; PMCID: PMC8501060.
  15. Houvenaeghel G, de Nonneville A, Cohen M, Classe JM, Reyal F, Mazouni C, Chopin N, Martinez A, Daraï E, Coutant C, Colombo PE, Gimbergues P, Chauvet MP, Azuar AS, Rouzier R, de Lara CT, Muracciole X, Agostini A, Gonçalves A, Lambaudie E. Isolated ipsilateral local recurrence of breast cancer: predictive factors and prognostic impact. Breast Cancer Res Treat. 2019 Jan;173(1):111-122. doi: 10.1007/s10549-018-4944-2. Epub 2018 Sep 20. PMID: 30238274.
  16. Nicolas C, Petit C, Tallet A, Boher JM, Varela Cagetti L, Favrel V, Gonzague Casabianca L, Guenole M, Mailleux H, Darreon J, Bannier M, Cohen M, Sabiani L, Tallet C, Teyssandier C, Gonçalves A, De Nonneville A, Lopez Almeida L, Coste N, Tyran M, Houvenaeghel G. Does Breast Surgery Type Alter Incidental Axillary Irradiation? A Dosimetric Analysis of the "Sentinel Envahi et Randomisation du Curage" SERC Trial. Cancers (Basel). 2024 Mar 19;16(6):1198. doi: 10.3390/cancers16061198. PMID: 38539532; PMCID: PMC10969031.
  17. Andersson Y, Bergkvist L, Frisell J, de Boniface J. Omitting completion axillary lymph node dissection after detection of sentinel node micrometastases in breast cancer: first results from the prospective SENOMIC trial. Br J Surg. 2021 Sep 27;108(9):1105-1111. doi: 10.1093/bjs/znab141. PMID: 34010418.
Publish with JBRES — Peer-reviewed, multidisciplinary Open Access with rapid review, DOI, and global visibility.
Double-Blind CrossRef DOI Discoverable
Submit Manuscript Membership